Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab

杨森在New Collab许可F-star的“柔性抗体”技术

2021-10-21 13:30:13 BioSpace

本文共950个字,阅读需3分钟

Clinical-stage biopharma company F-star Therapeutics announced a new partnership with Janssen Biotech on Wednesday, only one month after presenting an optimistic trial-in-progress update to the public on its tetravalent dual T-cell agonist FS120 at the European Society for Medical Oncology 2021 Conference. The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies in the hopes that they can use these custom-designed antibodies as part of their immuno-oncology research. F-star will be in entitled to $17.5 million in upfront and near-term fees, with room for additional milestones totaling $1.35 billion, as well as royalties on the annual net sales of any product using their technology. On top of that, they also saw a 9% increase in share value during premarket trading after the announcement. With its parent office in Cambridge, U.K., and U.S. branch operating out of Cambridge, Massachusetts, F-star specializes in the modification of natural human antibodies and their development into tetravalent bispecific antibodies. This is achieved by making substitutions in the Fc region of an immunoglobin antibody to create two additional antigen binding sites. Normally, these antibodies have three regions but only two binding sites, each of which is identical, such that one antibody can only recognize one type of antigen. The expansion allows for the recognition of a second type of antigen, or bispecificity. However, F-star’s technology can also be used to create tri-specific antibodies and fusion proteins. The technology behind these uniquely flexible antibodies allows them to be designed for custom immune activation, with the anticipation that they could be tailored to specific cancers and used to provoke a natural immune response. This makes them an encouraging prospect for the immuno-oncological treatments that Janssen is hoping to develop. “We are pleased to collaborate with Janssen and leverage the science of F-star’s proprietary tetravalent bispecific technology. Beyond our proprietary pipeline, we believe there is broad potential for our mAb2 platform to produce multiple next-generation bispecific antibody therapeutics,” said F-star Chief Scientific Officer Neil Brewis, Ph.D.   Johnson & Johnson’s Janssen conducts research and development programs across several subfields of medicine, such as immunology, oncology and neuroscience. The new license agreement with F-star is part of the company’s ongoing cancer interception research efforts. At present, Janssen has not revealed exactly what antigens it plans to target using F-star’s receptor substitution technology. However, the company’s dedication to immuno-oncology research has driven it to pursue additional license agreements, such as the one formed with Denmark’s Genmab A/S to develop a therapy using monoclonal antibodies, as well as explore several other potential targeted therapies for cancer treatment, including chimeric antigen receptor-T cell (CAR-T) therapy and T-cell redirection. Featured Jobs on BioSpace
临床阶段生物制药公司F-star Therapeutics周三宣布与让桑生物技术公司(Janssen Biotech)建立新的合作伙伴关系,仅一个月前,该公司在欧洲医学肿瘤学会2021年会议上向公众展示了其四价双T细胞激动剂FS120的乐观进展中的最新试验。 许可和合作协议允许让桑在新型双特异性抗体的研究、开发和商业化中使用F-STAR的专有技术,希望他们可以将这些定制设计的抗体作为免疫肿瘤学研究的一部分。 F-star将有权获得1750万美元的前期和近期费用,还有总额为13.5亿美元的额外里程碑,以及使用他们技术的任何产品的年度净销售额的版税。除此之外,在公告发布后的盘前交易中,他们的股价还上涨了9%。 F-star的母公司设在英国剑桥,美国分公司设在马萨诸塞州剑桥,专门从事天然人类抗体的修饰和四价双特异性抗体的开发。 这是通过在免疫球蛋白抗体的Fc区进行替换来产生两个额外的抗原结合位点来实现的。通常,这些抗体有三个区域,但只有两个结合位点,每个位点都是相同的,这样一种抗体只能识别一种类型的抗原。扩展允许识别第二类抗原,或双特异性。然而,F-STAR的技术也可用于创建三特异性抗体和融合蛋白。 这些独特灵活的抗体背后的技术允许它们被设计成定制的免疫激活,预计它们可以针对特定的癌症进行定制,并用于引发天然免疫反应。这使得它们成为Janssen希望开发的免疫肿瘤治疗的一个令人鼓舞的前景。 “我们很高兴与杨森合作,并利用F-STAR专有的四价双特异性技术的科学。除了我们的专有管道,我们相信我们的mAb2平台有广泛的潜力生产多种下一代双特异性抗体疗法,“F-star首席科学官尼尔·布鲁斯博士说 强生公司的杨森在医学的几个子领域进行研究和开发项目,如免疫学、肿瘤学和神经科学。与F-star的新许可协议是该公司正在进行的癌症拦截研究努力的一部分。 目前,Janssen还没有透露它计划使用F-STAR的受体替代技术针对什么抗原。然而,该公司致力于免疫肿瘤学研究,这促使它寻求额外的许可协议,如与丹麦Genmab a/S公司达成的使用单克隆抗体开发疗法的协议,以及探索其他几种潜在的癌症治疗靶向疗法,包括嵌合抗原受体T细胞(CAR-T)疗法和T细胞重定向。 生物空间上的特色工作

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文